맞춤형 의료에 대한 수요 증가, 시퀀싱 기술의 발전, 인간 건강과 질병에서 마이크로바이옴의 역할에 대한 이해도가 높아짐에 따라 마이크로바이옴 시퀀싱 서비스 시장이 성장하고 있다고 Verified Market Research의 애널리스트가 밝혔습니다. 마이크로바이옴 시퀀싱 서비스 시장은 2023년 약 16억 3,000만 달러 규모를 넘어 예측 기간인 2031년에는 40억 달러 규모에 달할 것으로 예상됩니다.
질병 예방, 진단 및 치료에서 마이크로바이옴의 역할에 대한 이해도가 높아지고, 학계와 바이오테크놀러지 간의 파트너십이 확대되면서 시장을 더욱 견인하고 있습니다. 이로 인해 2024-2031년 11.87%의 연평균 복합 성장률(CAGR)로 시장이 성장할 것으로 예상됩니다.
마이크로바이옴 시퀀싱 서비스 시장 정의/개요
마이크로바이옴 시퀀싱 서비스는 하이스루풋 시퀀싱 기술을 이용하여 인체, 토양 등 특정 환경에서 발견된 미생물의 유전 물질을 검출하고 분석하는 과정입니다. 이 서비스를 통해 미생물 군집의 구조와 기능에 대한 정확한 인사이트을 얻을 수 있으며, 건강과 질병에 대한 미생물의 역할을 더 깊이 이해할 수 있습니다.
또한 마이크로바이옴 시퀀싱은 헬스케어 등 다양한 용도로 활용되고 있으며, 염증성장질환, 비만, 당뇨 등의 질병에 대한 마이크로바이옴의 영향을 조사하여 궁극적으로 맞춤형 의료로 연결될 수 있습니다. 또한 농업 연구에서도 중요한 역할을 담당하고 있으며, 토양 마이크로바이옴을 분석하여 작물의 생산성을 향상시키고, 환경과학에서는 다양한 생태계에서 미생물의 다양성과 기능을 평가했습니다.
차세대 염기서열 분석(NGS)을 포함한 하이스루풋 시퀀싱 기술의 급속한 발전으로 미생물 유전체 염기서열 분석의 속도와 정확도가 향상되고 비용이 절감되고 있습니다. 이러한 기술 발전으로 마이크로바이옴 시퀀싱이 더욱 친숙해지고, 다양한 학술적 및 치료적 용도로 활용될 수 있게 되면서 이러한 서비스에 대한 수요가 증가하고 있습니다.
마이크로바이옴 시퀀싱은 농업, 환경과학, 제약 등 인간의 건강 외에도 다양한 분야에 적용되고 있습니다. 헬스케어 분야에서 마이크로바이옴 시퀀싱은 맞춤형 의료의 실현, 진단 방법의 개선, 새로운 치료법 창출에 활용되고 있습니다. 농업에서는 토양의 건강 상태와 작물 생산량을 개선하고 식물과 미생물의 상호 작용을 이해하는 데 도움이 됩니다. 이처럼 다양한 분야에서 용도가 확대되고 있는 것이 마이크로바이옴 시퀀싱 서비스 시장 확대에 박차를 가하고 있습니다.
또한 인간의 마이크로바이옴과 건강 및 질병에 미치는 역할에 대한 관심도 증가하고 있습니다. 이 분야의 연구를 통해 비만, 당뇨병, 자가면역질환, 자가면역질환, 정신건강 문제 등 다양한 질병에 대한 마이크로바이옴의 기능을 이해하게 되었습니다. 이처럼 마이크로바이옴 연구에 대한 관심이 높아지면서 미생물 군집을 정밀하게 분석하는 시퀀싱 서비스에 대한 수요가 급증하고 있습니다.
생성되는 방대한 양의 데이터 분석과 해석의 복잡성은 마이크로바이옴 시퀀싱 서비스 시장의 큰 장애물 중 하나입니다. 미생물 집단의 다양성과 다양한 환경 또는 숙주에서의 상호 작용으로 인해 데이터 분석은 특히 어렵습니다. 이러한 복잡성은 첨단 생물정보학 툴와 경험을 필요로 하므로 사내 역량이 없거나 최신 분석 플랫폼에 접근할 수 없는 연구자나 기업에게는 장애물이 되어 시장 확대를 제한하고 있습니다.
마이크로바이옴 조사에는 시료 채취, DNA 추출, 시퀀싱 프로토콜, 데이터 처리에 대한 표준화된 절차가 없습니다. 이러한 예측 불가능성으로 인해 연구 및 프로바이더 간 결과의 재현 및 비교가 어렵습니다. 세계에서 인정받는 표준과 방법론의 부재는 연구 결과의 평가와 비교를 어렵게 하고, 연구 추진과 마이크로바이옴 기반 애플리케이션 개발에 매우 중요한 역할을 하는 동시에 상업적 채택을 저해하고 있습니다.
The growing need for personalized medicine, advancements in sequencing technologies, and a greater comprehension of the microbiome's role in human health and disease are driving the market for microbiome sequencing services. According to the analyst from Verified Market Research, the Microbiome Sequencing Services Market is estimated to reach a valuation of USD 4 Billion over the forecast period 2031, subjugating around USD 1.63 Billion valued in 2023.
A growing understanding of the role of the microbiome in disease prevention, diagnosis, and treatment and the growth of academic-biotech partnerships, are further factors driving the market. It enables the market to grow at a CAGR of 11.87% from 2024 to 2031.
Microbiome Sequencing Services Market: Definition/Overview
Microbiome sequencing services are the process of detecting and analyzing the genetic material of microorganisms found in a specific environment, such as the human body or soil, using high-throughput sequencing technologies. This service gives precise insights into the structure and function of microbial communities, allowing for a better understanding of their roles in health and illness.
Furthermore, microbiome sequencing has a wide range of applications, including healthcare, where it is used to examine the impact of the microbiome on disorders such as inflammatory bowel disease, obesity, and diabetes, ultimately leading to personalized medication. It also plays an important role in agricultural research, analyzing soil microbiomes to increase crop productivity, and in environmental science, assessing microbial diversity and function in various ecosystems.
Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.
Rapid improvements in high-throughput sequencing technologies, including Next-Generation Sequencing (NGS), have reduced the cost of microbial genome sequencing while increasing its speed and accuracy. This technical advancement has made microbiome sequencing more accessible and possible for a variety of academic and therapeutic applications, resulting in increased demand for these services.
Microbiome sequencing has applications beyond human health, such as agriculture, environmental science, and pharmaceuticals. In healthcare, microbiome sequencing is used to produce personalized medicine, improve diagnostic methods, and create novel therapeutic tactics. In agriculture, it aids in improving soil health, crop output, and understanding plant-microbe interactions. This growing number of applications in many sectors has fueled the expansion of the Microbiome Sequencing Services Market.
Furthermore, there is a rising interest in examining the human microbiome and its role in health and disease. Research in this field has helped us understand the function of the microbiome in a variety of disorders, including obesity, diabetes, autoimmune diseases, and even mental health difficulties. This increased emphasis on microbiome research has resulted in a surge in demand for sequencing services to precisely analyze microbial communities.
The complexity of analyzing and interpreting the enormous volumes of data generated is one of the major obstacles to the Microbiome Sequencing Services Market. Data analysis is especially difficult due to the diversity of microbial populations and their interactions in various settings or hosts. This complexity demands sophisticated bioinformatics tools and experience, which creates an obstacle for researchers and enterprises without in-house capabilities or access to modern analytical platforms, limiting the market's expansion.
Microbiome research lacks standardized procedures for sample collection, DNA extraction, sequencing protocols, and data processing. This unpredictability makes it difficult to reproduce and compare results across studies and providers. The lack of globally acknowledged standards and methodologies makes it challenging to evaluate and compare findings, proving crucial for furthering research and developing microbiome-based applications and inhibiting commercial adoption.
According to VMR analyst, the sequencing by synthesis (SBS) segment is expected to dominate the segment within the Microbiome Sequencing Services Market. SBS technology, as represented by Next-Generation Sequencing (NGS) platforms such as Illumina's sequencing systems, has high-throughput capabilities, allowing for the simultaneous sequencing of millions of DNA molecules. This efficiency is critical for microbiome sequencing, which involves analyzing complex and diverse microbial communities. This capacity to process huge volumes of samples rapidly and efficiently is a key reason for SBS's dominant position in the market.
SBS technology ensures excellent precision and reliability in sequencing findings. It has a lower error rate than other sequencing technologies, which is important when identifying and measuring microbial species in a community. The great quality of SBS technology allows researchers and physicians to make educated judgements based on accurate and dependable data, contributing to its widespread adoption.
Furthermore, although the initial investment in SBS technology can be large, the per-sample cost of sequencing has dramatically lowered over the years as SBS technology has advanced and the market has become more competitive. This cost reduction has made SBS more accessible to a wider group of researchers and institutions, allowing for more comprehensive and diverse microbiome research programmes. SBS's low cost, combined with its high throughput and accuracy, make it an appealing choice for microbiome sequencing services.
The outsourced segment is estimated to hold the largest share of the Microbiome Sequencing Services Market during the forecast period. Outsourcing microbiome sequencing enables research organizations and businesses to leverage cutting-edge sequencing technologies and bioinformatics tools without incurring significant equipment and training costs. Service providers specialize in sequencing and have the experience and infrastructure to manage complicated projects, which can dramatically enhance sequencing quality and speed. This access is especially useful for small and medium-sized businesses and academic institutions that may lack the means to operate cutting-edge sequencing facilities in-house.
Furthermore, outsourced microbiome sequencing services provide greater flexibility and scalability than internal capabilities. Service providers can readily scale their operations up or down to meet the demands and specific needs of their clients, accommodating everything from tiny exploratory investigations to large-scale sequencing initiatives. This scalability enables research organizations to respond swiftly to changing project scopes and research goals, rather than being constrained by the capacity of their internal facilities.
According to VMR Analysis, the North American region is estimated to dominate in Microbiome Sequencing Services Market during the forecast period. North America is at the forefront of implementing advanced technology, such as next-generation sequencing (NGS), which is essential for microbiome sequencing. The region's openness to incorporate new technology into research and clinical practices improves its ability to perform large-scale microbiome studies, increasing in demand for sequencing services. The existence of leading sequencing technology businesses and startups in North America reinforces this trend.
Furthermore, in North America, there is a rising recognition of the microbiome's significance in health, illness, and environmental applications. This understanding is evident in the increased use of microbiome sequencing in a variety of disciplines, including healthcare, pharmaceuticals, agriculture, and environmental science. For example, in healthcare, there is a considerable emphasis on creating microbiome-based diagnostics, treatments, and personalized medicine. This broad application scope promotes demand for microbiome sequencing services, supporting regional market growth.
Asia Pacific is expected to grow at the highest CAGR in the Microbiome Sequencing Services Market during the forecast period. Countries in the Asia Pacific region, particularly China, Japan, South Korea, and Australia, are investing heavily in biotechnology R&D. This includes funding for the development of research infrastructure, including cutting-edge laboratories and sequencing facilities, as well as support for biotech firms and academic microbiome research programs. These investments are laying a solid platform for microbiome research and sequencing services, hence boosting market expansion.
Furthermore, the importance of the microbiome in human health, nutrition, and illness is becoming more widely recognized in Asia Pacific. This increased awareness is generating interest and research in fields such as probiotics, personalized medicine, and microbiome-based therapeutics. The rising prevalence of chronic diseases in the region, which may be connected to microbial imbalances is driving research activities and demand for sequencing services to better understand and treat these conditions.
The competitive landscape of the Microbiome Sequencing Services Market is marked by fierce competition among firms seeking to develop and broaden their offerings. Partnerships, collaborations, and acquisitions are also frequent tactics used by businesses to boost their market position, broaden their geographic reach, and improve their service offering.
Some of the prominent players operating in the Microbiome Sequencing Services Market include:
Charles River Laboratories, Eurofins Scientific, BGI, CosmosID, Microba, QIAGEN, Microbiome Insights, BaseClear, CD Genomics, Zymo Research, OraSure Technologies, MR DNA, Eremid Genomic Services, Clinical-Microbiomics A/S, Novogene Co., EzBiome, Boster Biological Technology, Zifo, Macrogen.
In May 2023, CosmosID presented new findings on the gut microbiome and its relationship with chronic inflammatory disorders at the American Gastroenterological Association (AGA) meeting.
In February 2023, Charles River Laboratories announced a collaboration with Danone Nutricia Research to create a microbiome research centre focusing on early-life nutrition and gut health.
In January 2024, Eurofins Scientific acquired LabWest, an Australian contract research organization (CRO), boosting its service offerings in Asia-Pacific, including microbiome testing.
In December 2023, BGI announced its new metagenomics sequencing tool, MGseq-1000, which provides researchers with a faster and more cost-effective choice for microbiome investigation.